biostudies-literatureLee JMBLRD VAThoracic Surgery Foundation for Research and Education NIH NCINCATS NIH HHSNHLBI NIH HHSNCI NIH HHSVANIH NCATSCSRD VANIH NCI4556-4568https://www.ebi.ac.uk/biostudies/studies/S-EPMC5599263biostudies-literatureUnknown23(16)<b>Purpose:</b> A phase I study was conducted to determine safety, clinical efficacy, and antitumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the <i>CCL21</i> gene (Ad-CCL21-DC). We evaluated safety and tumor antigen-specific immune responses following <i>in situ</i> vaccination (ClinicalTrials.gov: NCT01574222).<b>Experimental Design:</b> Sixteen stage IIIB/IV NSCLC subjects received two vaccinations (1 × 10⁶, 5 × 10⁶, 1 × 10⁷, or 3 × 10⁷ DCs/injection) by CT- or bronchoscopic-guided intratumoral injections (days 0 and 7). Immune responses were assessed by tumor antigen-specific periClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8⁺ T-cell Infiltration.PMC5599263U01 CA1964081I01CX000345-01NCIK23 CA131577U01 CA214182UL1 TR001881NCIR21 CA105705I01 BX000359P50 CA090388T32 CA009120R01 CA085686UL1-TR001881T32 HL072752NCI5 K12 CA076905R01 CA208403I01 CX000345NCIL30 CA142223R21 CA105705Lee SWalser TCWang GLin YMarincola FMSchaue DLee GSuh RGoldman JWDubinett SMLee JMSalehi-Rad RPark SJAbtin FWallace WDLee MHSharma SGaron ERosen FYanagawa JElashoff DAAdams SReckamp KLBaratelli FEZeng GTumeh PCfalsePhase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8⁺ T-cell Infiltration.<b>Purpose:</b> A phase I study was conducted to determine safety, clinical efficacy, and antitumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the <i>CCL21</i> gene (Ad-CCL21-DC). We evaluated safety and tumor antigen-specific immune responses following <i>in situ</i> vaccination (ClinicalTrials.gov: NCT01574222).<b>Experimental Design:</b> Sixteen stage IIIB/IV NSCLC subjects received two vaccinations (1 × 10⁶, 5 × 10⁶, 1 × 10⁷, or 3 × 10⁷ DCs/injection) by CT- or bronchoscopic-guided intratumoral injections (days 0 and 7). Immune responses were assessed by tumor antigen-specific peri2017-01-01T00:00:00Z2017 Aug2026-05-04T17:14:50.243Z2019-03-26T23:51:08ZS-EPMC55992632846894710.1158/1078-0432.CCR-16-282110.1158/1078-0432.ccr-16-2821